Navigation Links
Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital
Date:7/12/2010

BEIJING, July 12 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that effective as of July 1, 2010 it has entered into a joint venture with Chang'An Hospital for the operation of Chang'An Hospital's cancer treatment facilities by acquiring a 52% equity interest in Xi'an Wan Jie Hua Xiang Medical Technology Development Limited ("Wan Hua Tech"). Wan Hua Tech owns the land and building of Chang'An Hospital's cancer treatment facilities, which will be used for Chang'An CMS International Cancer Center (CCICC)'s future full operation. The purchase price for this acquisition is RMB103 million. Upon the acquisition, Concord Medical will be able to assume the preliminary operation of Chang'An Hospital's cancer treatment facilities to provide services to Chang'An Hospital.

During the preliminary operating period for Chang'An Hospital's cancer treatment facilities while waiting for the clinical license, the primary focus of the Chang'An Hospital's cancer treatment facilities will be on transitioning Chang'An Hospital cancer diagnosis and treatment facilities to CCICC, recruiting doctors and nurses and purchasing additional equipment. The selling equity holder of Wan Hua Tech is responsible for obtaining the clinical license, which will allow Concord Medical to provide cancer diagnosis and treatment services directly to patients.

About Concord Medical

Concord Medical operates the largest network of radiotherapy and diagnostic imaging facilities in China in terms of revenues and the total number of facilities in operation per available statistics. The Company currently operates a network of more than 89 centers spanning 37 cities and 21 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipments and manages the daily operations of its centers located on its hospital partners' premises. The Company provides ongoing training to doctors and other medical personnel in its network to ensure a high level of clinical care for patients.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; and technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For investor and media inquiries please contact:

    China

     Stephanie Song
     Concord Medical Services
     Tel:   +86-10-5957-5287
     Email: stephanie.song@cmsholdings.com

     Lilian Wong
     Brunswick Group, LLC
     Tel:   +86-10-6566-2256
     Email: lwong@brunswickgroup.com

    U.S.

     Nicki Kahner
     Brunswick Group, LLC
     Tel:   +1-212-333-3810
     Email: nkahner@brunswickgroup.com


'/>"/>
SOURCE Concord Medical Services Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concord Medical Files 2009 Annual Report on Form 20-F
2. Concord Medical Announces Share Repurchase Program
3. Concord Medical Announces New Centers Opening at Hospital Partner
4. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
5. Concord Grape Juice Has No Significant Impact on Body Weight
6. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
7. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
8. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
9. Partnership for Quality Medical Donations Commits to Long-Term Recovery in Haiti
10. ECRI Institute Adds 4,000 New Terms to Universal Medical Device Nomenclature System™
11. National Physician Staffing, Inc. Formed to Meet Current and Projected Increases in Demand for Medical Personnel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
Breaking Medicine News(10 mins):